Skip to main content
Fig. 3 | BMC Women's Health

Fig. 3

From: Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study

Fig. 3

Changes in pathological markers in patients with different treatment time to remission (< 6 months vs. ≥ 6 months). A Comparison of median IHC score values of ER, PR, PRB and Ki67 proteins at baseline assessment in patients that regressed < 6 months vs. ≥ 6 months. B Comparison of median change of IHC scores at 3–6 months treatment (T1) compared to baseline level (T0) in patients that regressed < 6 months vs. ≥ 6 months

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us